Original Article
 
Which patients with locally advanced pancreatic cancer treated with induction chemotherapy are most likely to benefit from post-induction chemoradiotherapy?
Sophie Otter1, Irene Chong2, Ria Kalaitzaki3, Diana Tait2
1Clinical Research Fellow, Royal Marsden Hospital, UK
2Consultant Clinical Oncologist, Royal, Marsden, Hospital, UK
3Senior Statistician, Royal Marsden Hospital, UK

Article ID: 100077Z04SO2018
doi: 10.5348/100077Z04SO2018OA

Corresponding Author:
Dr. Diana Tait,
Royal Marsden Hospital,
Downs Road, Sutton, UK, SM2 5PT

Access full text article on other devices

  Access PDF of article on other devices

[HTML Full Text]   [PDF Full Text] [Print This Article]
[Similar article in PubMed] [Similar article in Google Scholar]

How to cite this article
Otter S, Chong I, Kalaitzaki R, Tait D. Which patients with locally advanced pancreatic cancer treated with induction chemotherapy are most likely to benefit from post-induction chemoradiotherapy? Int J Hepatobiliary Pancreat Dis 2018;8:100077Z04SO2018.


ABSTRACT

Aims: The role of concomitant chemotherapy with radiotherapy (CRT) in locally advanced pancreatic cancer (LAPC) is controversial. The aim of this study was to report the outcomes of patients with LAPC treated with CRT over a 10-year period within a single institution and to identify those patients who derived the most benefit.

Methods: Patients with LAPC who received radical radiotherapy (> 45Gy) between January 2004 – October 2014 were identified. The Electronic Patient Record was reviewed to collect data regarding staging, treatment, response and outcome. The Kaplan-Meier and Cox regression methods were used to analyse survival outcomes and compare survival rates between groups. Results: 138 patients were identified. Patients who had a response on imaging after induction chemotherapy had a median OS of 17.4 months compared to 10.3 months in non-responders (HR 0.55, 95% CI 0.35–0.87, p=0.01). At three months post-radiotherapy, patients who had achieved a response on CT had a median OS of 56 months compared to 10.7 months (HR 0.28, 95% CI 0.12–0.65, p=0.003). However, a reduction in CA19-9 prior to radiotherapy was not significantly associated with progression free survival (PFS) or Overall survival (OS). Patients with a response in CA19-9 levels at 3-months post-radiotherapy compared to baseline had an OS of 19.1 months compared to 10.5 months in non-responders (HR 0.42, 95% CI 0.26–0.68, p<0.001).

Conclusion: Patients with LAPC who responded to chemotherapy on imaging prior to radiotherapy had improved PFS and OS than non-responders and therefore appeared to benefit the most from CRT. A decrease in CA19-9 prior to radiotherapy was not associated with improved survival and proved less useful for patient selection for CRT.

Keywords: Chemoradiotherapy, Pancreatic cancer, PET-CT


[HTML Full Text]   [PDF Full Text]

Author Contributions
Sophie Otter – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Irene Chong – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Ria Kalaitzaki – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Diana Tait – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Guarantor of Submission
The corresponding author is the guarantor of submission.
Source of Support
None
Conflict of Interest
Authors declare no conflict of interest.
Copyright
© 2018 Sophie Otter et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.